Skip to main content
AkademIndex

Products

For developers

AkademBaseOpen API for the ecosystem
← Back to work

Works cited by this work

55 works

Work: Exploring Cellular Immunotherapy Platforms in Multiple Myeloma

  1. Nano based drug delivery systems: recent developments and future prospects

    Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9

    Review article201811 citations
    ABI

  2. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Review article20236 citations
    ABI

  3. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

    S. Vincent Rajkumar

    Article20224 citations
    ABI

  4. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

    Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12

    Article20213 citations
    ABI

  5. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

    Jianjun Chu, Youcai Deng, D.M. Benson +13

    Article20133 citations
    ABI

  6. <i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection

    Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8

    Article20073 citations
    ABI

  7. Clinical relevance of host immunity in breast cancer: from TILs to the clinic

    Peter Savas, Roberto Salgado, Carsten Denkert +4

    Review article20153 citations
    ABI

  8. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

    Joseph D. Malaer, Porunelloor A. Mathew

    Article20173 citations
    ABI

  9. CAR-NK cells: A promising cellular immunotherapy for cancer

    Guozhu Xie, Han Dong, Yong Liang +3

    Review article20203 citations
    ABI

  10. Bispecifics, trispecifics, and other novel immune treatments in myeloma

    Guido Lancman, Joshua Richter, Ajai Chari

    Review article20203 citations
    ABI

  11. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

    Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2

    Review article20213 citations
    ABI

  12. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

    Ben Creelan, Chao Wang, Jamie K. Teer +23

    Article20213 citations
    ABI

  13. Antibody drug conjugate: the “biological missile” for targeted cancer therapy

    Zhiwen Fu, Shijun Li, Sifei Han +2

    Review article20223 citations
    ABI

  14. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer

    Feifei Li, Sheng Liu

    Review article20223 citations
    ABI

  15. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy

    Cheng Sun, Haoyu Sun, Weihua Xiao +2

    Review article20152 citations
    ABI

  16. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma

    Cheng Sun, Haoyu Sun, Cai Zhang +1

    Review article20142 citations
    ABI

  17. Are natural killer cells superior CAR drivers?

    Hans Klingemann

    Article20142 citations
    ABI

  18. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

    Sagar Lonial, Jamie Cavenagh

    Review article20092 citations
    ABI

  19. Personalized Dendritic Cell-Based Tumor Immunotherapy

    Nona Janikashvili, Nicolas Larmonier, Emmanuel Katsanis

    Review article20092 citations
    ABI

  20. Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

    Hua Jiang, Wenhao Zhang, Peipei Shang +10

    Article20132 citations
    ABI

  21. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells

    Loek J. Eggermont, Leonie E. Paulis, Jurjen Tel +1

    Review article20142 citations
    ABI

  22. Enhancement of Dendritic Cells as Vaccines for Cancer

    Meghan E. Turnis, Cliona M. Rooney

    Review article20102 citations
    ABI

  23. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6

    Marina Ratta, Francesco Fagnoni, Antonio Curti +9

    Article20022 citations
    ABI

  24. Regulation of Dendritic Cell Migration to the Draining Lymph Node

    Alfonso Martin‐Fontecha, Silvia Sebastiani, Uta E. Höpken +4

    Article20032 citations
    ABI

  25. Targeting B-Cell Maturation Antigen in Multiple Myeloma

    Yu‐Tzu Tai, Kenneth C. Anderson

    Review article20152 citations
    ABI